However, I’m reluctant to buy. Primary driver of the stock price seemed to be Ozempic. Weight-reduction dr-gs, therapies, diets have always had a short lifespan. It seems to me that Ozempic popularity is already waning, and that’s reflecting on the stock price. Besides Ozempic, I don’t know how robust Novo Nordisk is as a pharma company, and therefore how good of an investment in their stock can be in the long run.
There are no replies in this thread yet. Be the first to post a reply below: